ALTH Allos Therapeutics, Inc. (MM)

WESTMINSTER, Colo., Nov. 20 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced that the Company has been selected for inclusion in the NASDAQ Biotechnology Index (NBI), effective as of the market's open today, November 20, 2006. "We are very pleased to be included in the NASDAQ Biotechnology Index and believe that our selection is further recognition of our consistent progress and recent achievements" said Paul L. Berns, President and Chief Executive Officer. "We look forward to continuing to execute on our strategy to deliver innovative medicines that enhance and extend the lives of cancer patients." The NBI was launched in 1993 and includes biotechnology and pharmaceutical companies listed on the NASDAQ National Market that meet minimum requirements for market value, average daily share volume and seasoning as a public company. The NBI is ranked on a semi-annual basis in May and November and serves as the basis for the iShares Nasdaq Biotechnology Index Fund (AMEX: IBB). For more information about the Nasdaq Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com/. About Allos Therapeutics, Inc. Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company has two product candidates in late-stage clinical development: EFAPROXYN (efaproxiral), a radiation sensitizer currently under evaluation in a pivotal Phase 3 trial in women with brain metastases originating from breast cancer, and PDX (pralatrexate), a novel, next generation antifolate currently under evaluation in a pivotal Phase 2 trial in patients with relapsed or refractory peripheral T-cell lymphoma. The Company is also evaluating RH1, a targeted chemotherapeutic agent, in a Phase 1 trial in patients with advanced solid tumors. For additional information, please visit the Company's website at http://www.allos.com/. DATASOURCE: Allos Therapeutics, Inc. CONTACT: Jennifer Neiman, Manager, Corporate Communications of Allos Therapeutics, Inc., +1-720-540-5227, Web site: http://www.allos.com/

Copyright